Sumitomo Chemical's listed pharmaceutical subsidiary, Sumitomo Pharma, used a Tokyo Stock Exchange filing on August 12, 2026 to reject claims in a short seller's report and to flag that the report's author has disclosed a stock position tied to the outcome.
The report, published August 7 by Gotham City Research (GCR) under the title "Sumitomo Chemical and Sumitomo Pharmaceutical: Part II - CiRA, Dr. Yamanaka, and the undisclosed history of image duplication concerns," raises allegations tied to a body abbreviated in the title as "CiRA" and a researcher identified only as "Dr. Yamanaka". Sumitomo Pharma's statement, appended to its parent's filing, does not spell out which images, studies, or approval materials GCR says were duplicated. It states only that the report also contains references to one of Sumitomo Pharma's own products, and that GCR has disclosed holding a short position in the shares of the company its report targets, standing to profit if that stock falls.
On the product referenced in the report, Sumitomo Pharma says it was developed through years of collaboration with Kyoto University and other institutions, and that the company has verified the reliability of the data used in the drug's approval review. The therapy received a conditional, time-limited approval after scientific and medical review by regulators, according to the filing. Under the terms of that conditional approval, Sumitomo Pharma is running a Phase 4 post-marketing evaluation trial meant to build further evidence of the drug's efficacy and safety, with the aim of eventually securing full approval.
The rebuttal also references an earlier GCR report, published August 3, which the filing says was based on one-sided views of Sumitomo Pharma's financial reporting. Sumitomo Pharma says it will continue making timely and appropriate disclosures to shareholders and investors, and it warned it is prepared to pursue legal measures, where necessary, against inaccurate or misleading information that it says could harm the company and its investors.
What the filing does not do is resolve the substance of GCR's allegations. It is Sumitomo Pharma's own rebuttal, forwarded by parent Sumitomo Chemical, and it neither reproduces GCR's report nor offers independent verification of the image-duplication claims. It gives no completion date for the Phase 4 trial and no indication of whether legal action is imminent or merely under consideration. For now, investors weighing the dispute have only Sumitomo Pharma's flat rejection of a report from a research firm that has disclosed a short position designed to profit if the company it wrote about sees its shares fall.